CA Patent

CA2386270A1 — Rna interference pathway genes as tools for targeted genetic interference

Assigned to Carnegie Institution of Washington · Expires 2001-04-26 · 25y expired

What this patent protects

Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.

USPTO Abstract

Genes involved in double-stranded RNA interference (RNAi pathway genes) are identified and used to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity.

Drugs covered by this patent

Patent Metadata

Patent number
CA2386270A1
Jurisdiction
CA
Classification
—
Expires
2001-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Carnegie Institution of Washington
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.